PF-08634404 + Sigvotatug Vedotin + Combination Agent 1
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Non-Small Cell Lung Cancer
Conditions
Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Trial Timeline
Jan 30, 2026 → Aug 23, 2033
NCT ID
NCT07227298About PF-08634404 + Sigvotatug Vedotin + Combination Agent 1
PF-08634404 + Sigvotatug Vedotin + Combination Agent 1 is a phase 1/2 stage product being developed by Pfizer for Advanced/Metastatic Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07227298. Target conditions include Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07227298 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Advanced/Metastatic Non-Small Cell Lung Cancer